Welcome to our dedicated page for Treace Medical Concepts SEC filings (Ticker: TMCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Treace Medical Concepts, Inc. filings document the regulatory disclosures of a medical technology company focused on devices for bunion and related midfoot surgery. Its 8-K reports cover operating results, preliminary unaudited financial information, Regulation FD investor materials, press-release exhibits and Inline XBRL cover data.
The company’s SEC record also includes disclosures on material financing arrangements, including term loan and revolving loan agreements, as well as officer departures, board changes and committee matters. Proxy materials address annual meeting procedures, director elections, executive compensation, equity awards and corporate governance for the Delaware corporation.
Treace Medical Concepts Chief Innovation Officer Sean F. Scanlan reported equity transactions in company stock. On January 21, 2026, he exercised a stock option for 53,500 shares of Common Stock at an exercise price of $0.72 per share, converting a previously held option into directly owned shares. On January 22, 2026, he received a grant of 262,500 restricted stock units (RSUs), each RSU representing one future share of Common Stock upon vesting. The RSUs vest in equal annual installments over four years from January 22, 2027 through January 22, 2030, contingent on his continued service with the company.
Treace Medical Concepts, Inc. Chief Executive Officer John T. Treace, who is also a director and 10% owner, reported equity award activity in company common stock on January 22, 2026.
One transaction disposed of 14,254 shares of common stock at $0 per share, and another transaction added 250,000 restricted stock units (RSUs) at $0 per share. After these transactions, he directly beneficially owned 7,011,633 shares of common stock, which, according to the footnotes, include 571,871 RSUs.
The 250,000 RSUs vest in equal annual installments over four years, with vesting dates on January 22, 2027 through January 22, 2030, contingent on his continued service. Additional shares are held by his spouse and in related trusts, and he disclaims beneficial ownership of those holdings.
Treace Medical Concepts, Inc. Chief Financial Officer reports an insider stock transaction. On 01/10/2026, Mark Hair reported an "F" code transaction involving 8,719 shares of common stock at a reported price of $0 per share. Following this transaction, he beneficially owned 510,245 shares of Treace Medical Concepts common stock in direct form. A noted portion of this position consists of 398,009 restricted stock units, which typically represent share-based awards that may settle in stock over time.
Treace Medical Concepts, Inc. officer Elder Scot Michael, Chief Legal & Compliance Officer and Corporate Secretary, reported a transaction in company common stock dated 01/10/2026. A transaction coded "F" involved 4,544 shares at a reported price of $0 per share, after which he beneficially owned 543,737 common shares. This beneficial ownership figure includes 410,845 restricted stock units.
Treace Medical Concepts, Inc. reported an insider ownership update for Chief Executive Officer and director John T. Treace. On January 10, 2026, a Form 4 lists a transaction in which 13,219 shares of common stock were disposed of at a price of $0.00 per share under transaction code F, leaving 6,775,887 common shares directly beneficially owned. This direct position includes 363,867 restricted stock units.
The filing also reports additional indirect holdings of common stock attributed to Mr. Treace’s spouse and various trusts, with share amounts of 1,605,000, 1,471,250, 1,839,063, and 408,816. The reporting person disclaims beneficial ownership of shares held by his wife directly or in trusts she controls, as well as shares held in trusts for which he serves as trustee or co‑trustee.
Treace Medical Concepts reported that it has released certain preliminary unaudited financial results for the quarter and year ended December 31, 2025. These results are shared through a press release furnished as an exhibit and are not treated as formally filed financial statements. The company also posted an updated investor presentation on its investor relations website.
Treace plans to use this presentation in meetings with analysts and investors, including at the J.P. Morgan Healthcare Conference on January 14, 2026 at 7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time. A live webcast of this event, along with an archived recording and the presentation, will be available in the Investors section of the company’s website.
Treace Medical Concepts entered into new 60‑month credit facilities consisting of a term loan agreement with SLR Investment Corp. providing up to $125 million across four tranches and a revolving loan agreement with SLR Healthcare ABL providing a $30 million revolver, with potential increases to a total commitment of $50 million. The company drew $60 million at closing under the first term loan tranche. The term loan bears interest at 1‑Month SOFR plus 5.05%, while the revolver bears interest at 3‑Month SOFR plus 4.00%, with additional fees tied to servicing, unused capacity and early repayment.
The loans are secured by substantially all company assets and include a minimum liquidity requirement under which cash and cash equivalents in controlled accounts must exceed 60% of term loans outstanding, with revenue covenants applying if that test is not met. Treace used proceeds from the new term loan to repay and terminate its prior MidCap term and revolving credit agreements, paying $2.3 million in prepayment and exit fees. The new covenants limit the company’s ability to pay cash dividends unless financial conditions in the loan agreements are satisfied. The board also appointed long‑time director John K. Bakewell as lead independent director.
Treace Medical Concepts (TMCI) reported Q3 2025 results. Revenue was $50.2 million, up 11.4% year over year, as more bunion procedure kits were sold, partly offset by lower average selling prices on newer systems. Gross profit was $39.7 million. Operating expenses were $55.4 million, leading to a net loss of $16.3 million, or $0.26 per share.
For the first nine months of 2025, revenue reached $150.2 million and net loss was $49.6 million, or $0.79 per share. As of September 30, 2025, cash and cash equivalents were $7.7 million and marketable securities were $49.7 million. Total principal outstanding under the term and revolving loans was $54.0 million. Stockholders’ equity was $89.2 million. Shares outstanding were 63,718,073 as of October 31, 2025.
Management noted continued adoption of minimally invasive osteotomy solutions and competitive pressures, which have reduced average selling prices even as kit volumes increased.
Treace Medical Concepts (TMCI) furnished its Q3 2025 results via a press release attached as Exhibit 99.1. The information under Item 2.02 is furnished and not deemed filed under the Exchange Act.
The company also announced a board change. Richard W. Mott retired from the Board on November 3, 2025, for personal reasons and not due to any disagreement. On November 5, 2025, the Board reduced its size from eight to seven members; there are currently no vacancies.
Treace Medical Concepts (TMCI) reported an insider transaction on a Form 4. On 10/24/2025, the Chief Innovation Officer recorded a transaction in Common Stock with code F for 208 shares at $0, marked as a disposition. Following the transaction, the officer beneficially owns 373,599 shares, which includes 283,948 restricted stock units. Ownership is reported as direct.